Pharmaceutical restructuring is targeting HEOR and Market Access teams despite their critical role in commercial success.

Our report, Value in the Crosshairs, reveals why Value functions are vulnerable and provides a practical framework for demonstrating their commercial impact.

Discover how forward-thinking leaders are transforming Value teams from cost centers to strategic assets.

         Schedule a Call